IGM BIOSCIENCES DL-01
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M antibodies for the treatment of cancer and autoimmune and inflammatory diseases. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California. As of August 14, 2025, IGM Biosciences, In… Read more
Market Cap & Net Worth: IGM BIOSCIENCES DL-01 (1K0)
IGM BIOSCIENCES DL-01 (F:1K0) has a market capitalization of $40.57 Million (€39.52 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #26976 globally and #2953 in its home market, demonstrating a -0.92% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying IGM BIOSCIENCES DL-01's stock price €1.08 by its total outstanding shares 36593200 (36.59 Million).
IGM BIOSCIENCES DL-01 Market Cap History: 2019 to 2025
IGM BIOSCIENCES DL-01's market capitalization history from 2019 to 2025. Data shows change from $1.37 Billion to $40.57 Million (-36.89% CAGR).
IGM BIOSCIENCES DL-01 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how IGM BIOSCIENCES DL-01's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 1K0 by Market Capitalization
Companies near IGM BIOSCIENCES DL-01 in the global market cap rankings as of March 19, 2026.
Key companies related to IGM BIOSCIENCES DL-01 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
IGM BIOSCIENCES DL-01 Historical Marketcap From 2019 to 2025
Between 2019 and today, IGM BIOSCIENCES DL-01's market cap moved from $1.37 Billion to $ 40.57 Million, with a yearly change of -36.89%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | €40.57 Million | -82.00% |
| 2024 | €225.37 Million | -24.05% |
| 2023 | €296.74 Million | -47.68% |
| 2022 | €567.18 Million | -41.02% |
| 2021 | €961.59 Million | -63.94% |
| 2020 | €2.67 Billion | +95.05% |
| 2019 | €1.37 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of IGM BIOSCIENCES DL-01 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $40.57 Million USD |
| MoneyControl | $40.57 Million USD |
| MarketWatch | $40.57 Million USD |
| marketcap.company | $40.57 Million USD |
| Reuters | $40.57 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.